Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ: VRDN ) with a Buy and raises the price target from $35 to $38.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.